Eli Lilly announces the complete phase III data of new drugs for Alzheimer's disease, which may compete with Eisai at the end of the year
TRAILBLAZER-ALZ2 Design of experiments and summary of results. Image source: Journal of the American Medical AssociationOn July 17 local time, the United States Lilly (LLY...